Vistapharm/Pai Patent-Cliff Exposure & CMS Drug Spending Portfolio

Vistapharm/Pai (US): 3 reconciled FDA prescription therapies, $20K 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$20K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$20K
California HCAI SB 17 Filings7 WAC filings (max 21.6% 2-yr change)